While Mylan agreed to pay $465 million to resolve accusations it improperly classified EpiPens as a generic drug, the Canonsburg, Pa.-based drugmaker has yet to finalize the settlement with the Department of Justice, reports Reuters.
Supply Chain
After President Donald Trump said drugmakers were "getting away with murder" during his Jan. 11 press conference, leaders of the pharmaceutical industry responded with varying views.
Researchers at the Feinstein Institute for Medical Research in Manhasset, N.Y., are learning a new language to communicate with the body and redefine treatment of disease and injury — the language of bioelectronic medicine.
After withholding financial support from President-elect Donald Trump during last summer's Republican National Convention, United Parcel Service — along with several other major corporations — contributed to Mr. Trump's inaugural committee, reports The Wall Street Journal.
Mallinckrodt will pay $100 million to settle Federal Trade Commission claims that its U.S. subsidiary, Questcor, illegally raised the price of its autoimmune drug by 85,000 percent and purchased the rights to a cheaper version of the drug to keep…
Advertisement
Researchers discovered how drug spending is allocated across the pharmaceutical supply chain in a new study from Berkeley Research Group.
Here are six articles published by Becker's Hospital Review in the past week that highlight device issues or recalls, blood shortages and the fight against high drug prices, among other issues.
"Hospitals and health systems are experiencing an unprecedented escalation in the cost of older, commonplace drugs with new price increases," says Tom Fox, a managing director at healthcare consulting firm Novia Strategies.
The Food and Drug Administration is allowing Eisai Co. to sell its European-approved Panretin gel tubes in the U.S., despite an ongoing shortage of the FDA-approved version of the gel.
Novartis CEO Joe Jimenez said President-elect Donald Trump's plans to slash corporate tax rates may encourage Novartis to increase its investments in the U.S., reports Reuters.